Search Within

Nicole Alexa Schreiber

Refine Results
Formats
  1. Meeting Abstract (13)
  2. Journal Article (7)
Groups
  1. Genitourinary Oncology Service (20)
  2. Solid Tumor Oncology Division (20)
  3. Genitourinary Disease Management Team (16)
  4. Biostatistics Service (7)
  5. Epidemiology and Biostatistics (7)
  6. Molecular Imaging and Therapy Service (4)

More Groups

People
  1. Howard Scher (20)
  2. Martin Fleisher (14)
  3. Daniel Danila (11)
  4. Brigit McLaughlin (8)
  5. Glenn Heller (7)
  6. Richard Bambury (6)

More People

Years
  1. 2018 (3)
  2. 2017 (3)
  3. 2016 (5)
  4. 2015 (6)
  5. 2014 (1)
  6. 2013 (2)
Publications
  1. Journal of Clinical Oncology (7)
  2. Cancer Research (3)
  3. JAMA Oncology (3)
  4. Annals of Oncology (2)
  5. Clinical Cancer Research (1)
  6. European Journal of Cancer (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (7)
  2. American Association for Cancer Research (4)
  3. American Medical Association (3)
  4. Elsevier Science, Inc. (2)
  5. Oxford University Press (2)
  6. Elsevier Inc. (1)

More Publishers

Results (20)

Export to EndNote | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Winquist, E.; McLaughlin, B.; Lu, D.; Orr, S.; Fleisher, M.; Lowes, L.; Anderson, A. K. L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: A phase 2 clinical trial
    Journal Article

    Autio, K. A.; Dreicer, R.; Anderson, J.; Garcia, J. A.; Alva, A.; Hart, L. L.; Milowsky, M. I.; Posadas, E. M.; Ryan, C. J.; Graf, R. P.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Jayaram, A.; Winquist, E.; McLaughlin, B.; Lu, D.; Fleisher, M.; Orr, S.; Lowes, L.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes
    Meeting Abstract

    Scher, H.; Graf, R. P.; Jendrisak, A.; McLaughlin, B.; Barnett, E.; Schreiber, N. A.; Lee, J.; Kelvin, J.; Wang, Y.; Landers, M.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer
    Journal Article

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; McLaughlin, B.; Jendrisak, A.; Wang, Y.; Lee, J.; Greene, S.; Krupa, R.; Lu, D.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; McLaughlin, B.; Lu, D.; Louw, J.; Danila, D. C.; Dugan, L.; Johnson, A.; Heller, G.; more...
    European Urology (2017)

    Fulltext@MSK | Save
  • Impact of AR-V7 protein localization in the prediction of therapeutic benefit of taxanes over androgen receptor signaling inhibitors (ARSi) in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H.; Graf, R.; Schreiber, N.; Lu, D.; Louw, J.; Alvarez, H. A. V.; Bambury, R.; Danila, D.; McLaughlin, B.; Heller, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Lu, D.; Schreiber, N. A.; Louw, J.; Graf, R. P.; Vargas, H. A.; Johnson, A.; Jendrisak, A.; Bambury, R.; Danila, D.; more...
    JAMA Oncology (2016)

    Fulltext@MSK | Save
  • Clinical validity of detecting circulating tumor cells by AdnaTest assay compared with direct detection of tumor mRNA in stabilized whole blood, as a biomarker predicting overall survival for metastatic castration-resistant prostate cancer patients
    Journal Article

    Danila, D. C.; Samoila, A.; Patel, C.; Schreiber, N.; Herkal, A.; Anand, A.; Bastos, D.; Heller, G.; Fleisher, M.; Scher, H. I.
    The Cancer Journal (2016)

    Fulltext@MSK | Save
  • Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients
    Meeting Abstract

    Scher, H. I.; Graf, R.; Louw, J.; Jendrisak, A.; Johnson, A.; Greene, S.; Rodriguez, A.; Schreiber, N. A.; McLaughlin, B.; Dugan, L.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save